Table 3 Logistic regression model of antiparkinsonian drugs significantly associated with depression and anxiety
From: Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease
Antiparkinsonian treatment | Patients with depression | Patients without depression | Adjusted OR (95% CI) | P value | Patients with anxiety | Patients without anxiety | Adjusted OR (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|
L-DOPA (mg/d) | 385.50 | 238.70 | 1.000(0.999–1.002) | 0.877 | 365.72 | 218.87 | 1.001(0.999–1.002) | 0.266 |
Dopamine agonist (mg/d) | 52.00 | 41.79 | 1.002 (0.995–1.009) | 0.662 | 53.12 | 39.53 | 1.005 (1.000–1.007) | 0.073 |
MAO-B inhibitor (mg/d) | 15.00 | 18.86 | 0.993 (0.981–1.005) | 0.232 | 16.8 | 18.92 | 1.001 (0.993–1.010) | 0.763 |
COMT inhibitor (mg/d) | 10.12 | 4.22 | 0.997 (0.984–1.007) | 0.607 | 8.94 | 3.57 | 1.003(0.992–1.014) | 0.575 |
Amantadine (mg/d) | 44.00 | 43.86 | 0.996 (0.992–1.001) | 0.106 | 56.73 | 39.36 | 1.003 (1.000–1.006) | 0.092 |